Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prescription of anti-osteoporosis drugs during 2004-2007—a nationwide register study in Norway.Eur J Clin Pharmacol. 2010; 66: 299-306
- Uncovering the cause of “phossy jaw” Circa 1858 to 1906: oral and maxillofacial surgery closed case files-case closed.J Oral Maxillofac Surg. 2008; 66: 2356-2363
- Osteonecrosis of the jaw and the role of macrophages.J Natl Cancer Inst. 2011; 103: 232-240
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.J Oral Maxillofac Surg. 2003; 61: 1115-1117
- Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.J Oral Maxillofac Surg. 2004; 62: 527-534
- American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.J Oral Maxillofac Surg. 2007; 65: 369-376
- Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.J Bone Miner Res. 2007; 22: 1479-1491
- Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.J Rheumatol. 2009; 36: 2780-2787
- Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.J Am Dent Assoc. 2009; 140: 61-66
- Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.J Bone Miner Res. 2008; 23: 826-836
- Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis.J Natl Cancer Inst. 2007; 99: 1016-1024
- Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.J Clin Oncol. 2006; 24: 945-952
- Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.J Oral Maxillofac Surg. 2007; 65: 415-423
- Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.J Oral Maxillofac Surg. 2010; 68: 243-253
- ONJ in two dental practice-based research network regions.J Dent Res. 2011; 90: 433-438
- Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study.J Rheumatol. 2008; 35: 691-695
- Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN.J Dent Res. 2011; 90: 439-444
- Osteonecrosis of the jaw: an update and review of recommendations.Cells Tissues Organs. 2009; 189: 275-283
- Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.J Bone Miner Res. 2010; 25: 2267-2294
- Severely suppressed bone turnover: a potential complication of alendronate therapy.J Clin Endocrinol Metab. 2005; 90: 1294-1301
- Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.N Engl J Med. 2008; 358: 1304-1306
- An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?.Injury. Feb 2008; 39: 224-231
- Atypical femoral fractures and bisphosphonate use.N Engl J Med. 2010; 362: 1848-1849
- Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?.J Orthop Trauma. 2010; 24: 75-81
- Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.J Bone Miner Res. 2011; 26: 553-560
- Fragility fractures of the hip and femur: incidence and patient characteristics.Osteoporos Int. 2010; 21: 399-408
- A retrospective analysis of all atypical femur fractures seen in a large california HMO from the Years 2007 to 2009.J Bone Miner Res. 2010; 25
- Bisphosphonate use and atypical fractures of the femoral shaft.N Engl J Med. 2011; 364: 1728-1737
- Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.J Bone Miner Res. 2009; 24: 1095-1102
- Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.N Engl J Med. 2010; 362: 1761-1771
- Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.J Bone Miner Res. 2010; ([Epub ahead of print])
- Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.Osteoporos Int. 2009; 20: 1353-1362
- Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.JAMA. 2011; 305: 783-789
- Pamidronate: an unrecognized problem in gastrointestinal tolerability.Osteoporos Int. 1994; 4: 320-322
- Multiple ulcerative esophagitis caused by alendronate.Am J Gastroenterol. 1995; 90: 1889-1890
- Alendronate-associated esophagitis: endoscopic and pathologic features.Gastrointest Endosc. 1998; 47: 525-528
- Alendronate-associated esophageal injury: pathologic and endoscopic features.Mod Pathol. 1999; 12: 1152-1157
- Fatal esophageal perforation with alendronate.Am J Gastroenterol. 2001; 96: 3212-3213
- Reports of esophageal cancer with oral bisphosphonate use.N Engl J Med. 2009; 360: 89-90
- Esophageal adenocarcinoma incidence: are we reaching the peak?.Cancer Epidemiol Biomarkers Prev. 2010; 19: 1468-1470
- Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.J Natl Cancer Inst. 2008; 100: 1184-1187
- The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.J Natl Cancer Inst. 2005; 97: 142-146
- More on reports of esophageal cancer with oral bisphosphonate use.N Engl J Med. 2009; 360 ([author reply: 1791–2]): 1789-1790
- More on reports of esophageal cancer with oral bisphosphonate use.N Engl J Med. 2009; 360 ([author reply: 1791–2]): 1789
- Exposure to oral bisphosphonates and risk of esophageal cancer.JAMA. 2010; 304: 657-663
- Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.BMJ. 2010; 341: c4444
- Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus.Dig Dis Sci. 2010; 55: 3404-3407
- Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.Osteoporos Int. 2011; 22: 373-390
- Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.JAMA. 2006; 296: 2927-2938
- Ten years’ experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med. 2004; 350: 1189-1199
- Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.J Bone Miner Res. 2010; 25: 976-982
- Fracture risk remains reduced one year after discontinuation of risedronate.Osteoporos Int. 2008; 19: 365-372
- Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.Osteoporos Int. 2008; 19: 1613-1620
Article info
Footnotes
Financial disclosure/conflict of interest: JRC—consulting/honoraria: Amgen, Merck, Novartis, Roche, Lilly; KGS—consulting/honoraria: Amgen, Lilly, Merck, Novartis.
This project was supported by Grant Number T32HS013852 from the Agency for Healthcare Research and Quality (JZ), by Grant Number AR053351 from the National Institutes of Health (JRC), and by Grant Number R01HS018517 from the Agency for Healthcare Research and Quality (JRC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.
Identification
Copyright
© 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
